MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
Rhea-AI Summary
MIMEDX (NASDAQ:MDXG) has announced a strategic collaboration with Vaporox, establishing co-promotion and co-marketing of MIMEDX's placental allograft portfolio alongside Vaporox's Vaporous Hyperoxia Therapy (VHT) device. The partnership includes a strategic investment by MIMEDX in Vaporox and exclusive rights for potential acquisition discussions.
Vaporox's FDA-cleared VHT device combines ultrasonic mist and concentrated oxygen to treat nine types of chronic wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers. Clinical studies have shown wound healing rates exceeding 80% at 20 weeks when VHT is combined with standard wound care, with promising results when used with MIMEDX's EPIFIX® products.
Positive
- Strategic investment and exclusive acquisition rights in Vaporox strengthen MIMEDX's market position
- VHT device has FDA 510(k) clearance for treating nine types of wounds
- Clinical studies show over 80% wound healing rates at 20 weeks
- Complementary technology shows promising results with MIMEDX's EPIFIX products
- Partnership expands MIMEDX's portfolio diversification in wound care
Negative
- Financial terms and investment amount not disclosed
- Market penetration timeline and revenue impact unclear
News Market Reaction
On the day this news was published, MDXG declined 2.25%, reflecting a moderate negative market reaction. Argus tracked a peak move of +14.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $27M from the company's valuation, bringing the market cap to $1.18B at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions.
Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy (“VHT”) device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a single device and has received a 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to treat nine types of wounds, including Diabetic Foot Ulcers (“DFUs”), Venous Leg Ulcers (“VLUs”) and Pressure Ulcers (bed sores).
“We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,” commented Joseph H. Capper, MIMEDX Chief Executive Officer. “Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.”
“Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology,” said Alan Sage, Chief Executive Officer of Vaporox. “We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering—allowing us to reach more patients with these highly complementary offerings.”
VHT has been the subject of three IRB clinical studies, each of which demonstrated wound healing rates exceeding
About Vaporox, Inc.
Vaporox’s technology represents a breakthrough in treating chronic wounds. The company is focused on superior healing outcomes while reducing costs across a wide range of healthcare settings. With strong clinical results and growing adoption, Vaporox empowers providers to restore hope and healing for patients suffering from chronic wounds.
For additional information, please visit https://www.vaporox.com/.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What is the strategic collaboration between MIMEDX (NASDAQ:MDXG) and Vaporox?
What is Vaporox's VHT device and what conditions does it treat?
What are the clinical results of Vaporox's VHT therapy?
How does the Vaporox VHT device complement MIMEDX's EPIFIX products?
What are the financial terms of MIMEDX's investment in Vaporox?
